Key Insights

Highlights

Treatment Research

2 treatments under study, led by Gammasecretasenotch Signalling Pathway Inhibitor Ro4929097

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT01120275Phase 2Terminated

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Showing all 1 trials

Research Network

Common Treatments

  • Gammasecretasenotch Signalling Pathway Inhibitor Ro49290971
  • Laboratory Biomarker Analysis1

Active Sponsors

  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Superficial Spreading Malignant Melanoma1
  • Lentigo Maligna Malignant Melanoma1
  • Solar Radiationrelated Skin Melanoma1
  • Stage Iv Melanoma1
  • Acral Lentiginous Malignant Melanoma1

Activity Timeline